antibodies and receptors, cabbages, and kings

[Guest guest]

> Date: Sun, 31 Aug 2003 03:16:05 -0000

> From: " Sally " <salpal@...>

>Subject: Re: how true is this?

>

>Hi ,

>

>I just finished talking to in her chat and guess what? She is

>in the middle of a bad relapse and is going to have a test to see if

>she is building up antibodies to Avonex. Her doc wants he to go on

>Rebif, but if she is progressing on the abcr drugs, SHE WILL GET

>LDN!! She is no longer talking against LDN, and I think that is a

>good sign. I think is an open minded person, who only wants

>what is best for herself and all msers......And if LDN works for

>her, that would be one very strong naysayer on ldn's side. She is a

>very strong voice for her chatroom and the people there trust her to

>be honest with them.....So let's pray that she does the best

>thing....whatever that may be....and I hope, of course, that it will

>be LDN

>

>Hugs, Sally

Since there are a lot of people with MS in this group, even though it

is for all of the diseases that are treatable with LDN therapy, I feel

it should be said that:

Avonex and Rebif are chemically the same! Neutralizing antibodies (NABs)

to them should be the same as well. They are both interferon beta-1a. They

come from different cell lines, one human and one hamster, but I don't see

why Rebif will work if you have been on Avonex and had a relapse and have

NABs to beta-1a.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve & db=PubMed & list_ui

ds=9595973 & dopt=Abstract

There has been haggling and controversy, first over whether Rebif should

be sold in the US at all since it was the same chemical, and then which

therapy worked better or longer.

http://www.fda.gov/cber/adpromo/ifnbbio050902.htm

....

I have also recently seen discussion of whether Naltrexone is an opiate

itself or an opiate antagonist. At the concentration approved for Revia

for narcotic addiction it is definitely an opiate receptor antagonist.

However, there are several papers that offer the newer theory that many

drugs

have dual properties as both opiate receptor antagonists, and agonists,

depending on the *concentrations*, and that there are different types of

receptors, both inhibitory and excitatory. Ultra low doses of

Naltrexone have been used as excitatory receptor antagonists while

simultaneously morphine was used as an inhibitory receptor agonist. Since

these excitatory receptors are blamed for the pain reactions due to opiate

withdrawal, and possibly for some of the " psychological " dependence,

it may be possible to prevent both withdrawal symptoms, and return to

addiction, using excitatory receptor antagonists.

http://www.ampainsoc.org/abstract/2000/data/45/

So which is our usage of naltrexone? It may be acting, as the web page

suggests, as a short-term (over in 4-6 hours) antagonist to the inhibitory

receptors which are stimulated by endorphins, and higher endorphin

production

gets triggered by this. So users feel only the " next day " effects of extra

endorphins, and these contribute both to the increased feeling of wellness

and to some action that counters the inflammatory action of MS's failing to

recognize our own myelin. So " progress " of MS is halted. This action may

be

the excitatory receptor antagonism which is experienced when naltrexone,

naloxone and other drugs, normally used at higher doses, are used in

very low concentrations. If true, we might see similar results at 10 times

or lower doses, and there may be ways of unmasking these effects further

using simultaneous doses of other substances, especially afer Naltrexone

has been used for some time, and some tolerance to it established

(tachyphylaxis?).

The US Government has produced a 350 page paper on immuno-augmentation and

Naltrexone (LDN) therapy for the treatment of cancer. It was an assessment

of best cases treated at " Complementary and Alternative Medicine " providers,

under which umbrella it included Dr. Bilhari. I hope he take it as a

" complement " .

It concluded that " for Naltrexone, a prospective cohort case series should

be

considered " , as of its publication, April 2003. Considered by whom it

didn't

say.

http://www.ahcpr.gov/clinic/evrptfiles.htm

I think studies should be done on the effect of low dose Naltrexone and

perhaps similar drugs, on MS. The drug companies might be interested if

they can find a way to patent it and bottle it. Anyway I think it is a

very promising area of research for *somebody*.

-Sullivan